The $17.3 billion deal could negatively affect drugmakers, insurers and pharmacy benefit managers, particularly CVS Health — which owns one of the largest PBMs in the nation, according to the report.
As PBM for Wellcare, CVS Health currently gets a cut of $15 billion to $20 billion of Wellcare’s annual drug spending. The Centene acquisition would be a major loss for CVS if Centene’s PBM, RxAdvance, replaces CVS.
Humana may also be negatively affected, according to Barron’s. Humana investors have been upset that the insurer didn’t aggressively seek a deal to get more involved in Medicaid. The Centene-WellCare combination has effectively removed two potential Medicaid deal partners and would create a stronger competitor for the health insurer.
Read the full report here.
More articles on payers:
Trump administration sued over New Hampshire’s Medicaid work requirements
5 must-reads on payer-provider relationships
Sutter Health, Anthem sign new contract
